ARK Genomic Revolution ETF vs Braze Inc — how do they compare? ARK Genomic Revolution ETF trades at $44.4, while Braze Inc trades at $27.62 (market cap $3.18B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Braze Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | BRZE | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $44.55 | $36.19 |
52-Week Low | $24.02 | $15.79 |
Market Cap | — | $3.18B |
Enterprise Value | — | $2.87B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Braze (BRZE) trades at $27.71, down 3.62% today, with strong analyst support (96% buy ratings) and a $34.78 consensus price target. The stock shows bullish technical momentum despite recent earnings misses, with revenue growing 30% year-over-year to $593M in 2025. Recent news highlights insider selling and AI-driven sector recovery, while the company maintains robust gross margins of 66.5% but remains unprofitable with a -15.5% net margin.
The outlook remains positive based on accelerating revenue growth and strong institutional backing, though profitability challenges and recent insider selling present near-term risks. With technical indicators showing bullish momentum and the stock trading below analyst targets, BRZE offers growth potential but requires monitoring of execution on path to profitability.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →